The effect of the presence of metabolic syndrome criteria on the post-infarction course in patients with acute myocardial infarction with ST-segment elevation

Main Article Content

O. V. Shumakov
O. M. Parkhomenko
O. V. Dovhan
O. S. Gurjeva


The aim – to assess the additional prognostic information of metabolic syndrome (MS) components in groups of patients with acute myocardial infarction with segment elevation ST (STEMI), equalized in terms of commonly used acute coronary syndrome (ACS) risk factors.
Materials and methods. Retrospective analysis of the 820 cases of STEMI included: evaluation of risk factors according to the scales TIMI, GRACE, PURSUIT, and evaluation of components of the metabolic syndrome at entry (the presence of diabetes mellitus and/or increasing glucose levels > 7 mmol/l, overweight, hypertension, dyslipidemia), as well as the assessment of the indicators of clinical course of hospital period of MI, treatment and results of follow-up of patients, including the information about cases of cardiac death.
Results and discussion. Via automated «case-match-control» algorhythm from the basic cohort 2 groups were selected: group 1 (n=41, patients with MS) and group 2 (n=123, patients without MS). Matching criteria included following 13 risk factors: age, height, presence of heart failure, smoking, systemic hypotension at the 1 day of AMI, presence of anterior STEMI, the peak level of the MB-CK and AST, a history of angina and the period of unstable angina before STEMI, the presence of previous MI, baseline heart rate, baseline glomerular filtration rate (CKD-EPI), male gender. Groups were exactly matched by the first 4 matching criteria, and among other criteria maximum mismatch of 3 criteria was allowed (mean mismatch was 1.87 criteria from 13 per pair, and there were no significant differences in groups by each of 13 matching criteria). Otherwise, group 1 was characterized by more severe baseline profile, clinical course of hospital period, but it has the more intensive medical treatment also (including more frequent prescription of ACE inhibitors). According to the follow-up data, patients in group 1 had smaller end-systolic and end-diastolic indexes, more signed improvement in acute heart failure rate, higher heart rate variability and smaller dispersion of repolarisation at the 10th day. Also there was observed a trend toward a lower 3-year mortality (4,9 versus 17,1 %; p=0.05).
Conclusions. The presence of MS accompanying STEMI is associated with poorer course of acute period of the disease and, in a contrary, with more favorable course of post-infarction period because of more intensive cardiac therapy in this group of patients.

Article Details


acute coronary syndrome, metabolic syndrome, prognosis, post-infarction period


Пархоменко О.М., Шумаков О.В., Іркін О.І. та ін. Деклараційний патент на винахід UA № 53855 А. Спосіб визначення схильності до розвитку стійкої шлуночкової тахікардії в підгострій фазі інфаркту міокарда. Опубл. 17.02.2003, Бюл. № 2.

Шумаков О.В., Пархоменко О.М., Іркін О.І. и др. Особенности клинического течения и электро­­­физиологических показателей у больных с острым инфарктом миокарда и сопутствующей артериальной гипертензией: результаты исследования «случай – контроль» // Укр. кардіол. журн.– 2009.– № 6.– С. 7–13.

Alberti K., Zimmet P., Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation // Diabet Med.– 2006.– Vol. 23 (5).– P. 469–480. doi: 01858.x.

Arnold S., Lipska K., Li Y. et al. The reliability and prognosis of in-hospital diagnosis of metabolic syndrome in the setting of acute myocardial infarction // J. Am. Coll. Cardiol.– 2013.– Vol. 62.– P. 704–708. doi:

Borrayo-Sánchez G., Rosas-Peralta M., Ramírez-Arias E. et al. STEMI and NSTEMI: Real-world Study in Mexico (RENASCA) // Arch. Med. Research.– 2018.– Vol. 49 (8).– P. 609–619. doi:

Concalves P., Ferreira J., Aguiar C. et al. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS // Eur. Heart. J.– 2005.– Vol. 26 (9).– P. 865–872. doi:

Hajsadegh S., Chitsazan M., Chitsazan M. et. al. Metabolic Syndrome is Associated With Higher Wall Motion Score and Larger Infarct Size After Acute Myocardial Infarction // Res. Cardiovasc.– 2015.– Vol. 4.– Р. e25018. doi:

Huang P. A comprehensive definition for metabolic syndrome // Dis. Model Mech.– 2009.– Vol. 2 (5–6).– P. 231–237. doi:

Iannuzzi G., Maniscalco M., Elia A. et al. Left ventricular hypertrophy as protective factor after bypass grafting // Med. Hypotheses.– 2018.– Vol. 114.– P. 35–39. doi:

Ibanez B., James S., Agewall S. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) // Eur. eart J.– 2018.– Vol. 39 (2).– P. 119–177. doi:

Jacobs D., Kroenke C., Crow R. et al. PREDICT: A Simple Risk Score for Clinical Severity and Long-Term Prognosis After Hospitalization for Acute Myocardial Infarction or Unstable Angina // Circulation.– 1999.– Vol. 100.– P. 599–607. doi:

Kannel W.B. Risk stratification in hypertension: new insights from the Framingham Study // Am. J. Hypertens.– 2000.– Vol. 13 (Suppl.1).– P. S3–S10. doi:

Kastelein J., Holme I., Barter Ph. et al. Superiority of ApoB/ApoA1 Ratio for Predicting Cardiovascular Risk in Pooled Analyses of the Incremental Decrease in Endpoints through Aggressive Lipid-Lowering (IDEAL) and Treating to New Targets (TNT) Trials // Circulation.– 2006.– Vol. 114.– P. 713–714. doi:

Lin C., Lee P., Chen K. et al. Clinical, demographic, and biochemical characteristics of patients with acute st-segment elevation myocardial infarction: an analysis of acute coronary syndrome registry data of a single medical center from 2005 to 2016 // Acta Cardiol.– 2020.– Vol. 36 (1).– P. 1–7. doi:

Malliani A., Pagani M., Lombardi F. et al. Cardiovascular neural regulation explored in the frequency domain// Circulation.– 1991.– Vol. 84.– P. 1482–1492. doi:

Mente A., Yusuf S., Islam S. et al. Metabolic Syndrome and Risk of Acute Myocardial Infarction: A Case-Control Study of 26,903 Subjects From 52 Countries // J. Am. Coll. Cardiol.– 2010.– Vol. 55.– P. 2390–2398. doi:

Mornar Jelavic M., Babic Z., Pintaric H. Metabolic syndrome: influence on clinical severity and prognosis in patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention // Acta Cardiol.– 2015.– Vol. 70 (2).– P. 149–156. doi:

Patel R., Su Sh., Neeland I. The chromosome 9p21 risk locus is associated with angiographic severity and progression of coronary artery disease // Eur. Heart J.– 2010.– Vol. 31.– P. 3017–3023. doi:

Reuter H., Hoffmann F., Zander W. et al. Arterial hypertension as prognostic marker in patients with ST-elevation myocardial infarction and early percutaneous coronary intervention // J. Hypertension.– 2017.– Vol. 35.– P. e29. doi:

Romero-Corral A., Somers V., Sierra-Johnson J. et al. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality // Eur. Heart J.– 2010.– Vol. 31 (6).– P. 737–746. doi:

Sarkar S., Paul B., Chakraborty P. et al. Association between Metabolic Syndrome and Acute Myocardial Infarction (AMI) // Mymensingh Med. J.– 2016.– Vol. 25 (4).– P. 628–634. PMID:27941721

Schnabel R., Schulz A., Messow C. et al. Multiple marker approach to risk stratification in patients with stable coronary artery disease // Eur. Heart J.– 2010.– Vol. 31.– P. 3024–3031. doi:

Thomas F., Rudnichi A., Bacri A. et al. Cardiovascular mortality in hypertensive men according to presense of associated risk factors // Hypertension.– 2001.– Vol. 37.– P. 1256–1261. doi:

Uppalakal B., Karanayil L. Incidence of metabolic syndrome in patients admitted to medical wards with ST elevation myocardial infarction // J. Clin. Diagn. Res.– 2017.– Vol. 11 (3).– P. 17–20. doi:

Van De Borne P., Montano N., Narkiewicz K. et al. Impor­­­tance of ventilation in modulating interaction between sympathetic drive and cardiovascular variability // Am. J. Physiol. Heart Circ. Physiol.– 2001.– Vol. 280.– P. 722–729. doi:

Yusuf S., Hawken S., Ounpuu S., on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study // Lancet.– 2004.– Vol. 364.– P. 937–952. doi:

Zeller M., Steg Ph., Ravisy J. et al. Relation between body mass index, waist circumference, and death after acute myocardial infarction // Circulation.– 2008.– Vol. 118.– P. 482–490. doi:

Most read articles by the same author(s)

1 2 3 > >>